A comprehensive evidence-based resource mapping HBOT applications across all clinical departments — from FDA-approved indications to emerging longevity and wellness protocols. Structured for clinical and executive decision-making.
14
FDA-Approved Indications
UHMS recognized conditions
>20%
Telomere Lengthening
In healthy older adults (60 sessions)
258
Peer-Reviewed Citations
Supporting the evidence base
2–3
Treatment Pressure
Standard therapeutic range
HBOT exerts its therapeutic effects through five distinct and complementary physiological mechanisms, each contributing to its broad clinical applicability.
HBOT reverses tissue hypoxia while simultaneously inducing vasoconstriction, reducing edema without compromising oxygen delivery.
At 3.0 ATA breathing 100% oxygen, dissolved plasma oxygen increases by approximately 42%, providing sufficient oxygen to sustain cellular respiration even in the absence of hemoglobin. This is particularly beneficial in compartment syndrome and traumatic brain injury.
Hyperoxia stimulates VEGF, PDGF, and FGF release, promoting capillary budding and granulation tissue formation in chronic wounds.
Vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) are upregulated under hyperoxic conditions. This cascade promotes new blood vessel formation, critical for wound healing and tissue regeneration.
High oxygen tensions enhance leukocyte oxidative killing capacity and are directly lethal to anaerobic bacteria such as Clostridium perfringens.
Oxygen is utilized by neutrophils and macrophages to generate reactive oxygen species (ROS) that destroy bacteria. HBOT is directly bactericidal to obligate anaerobes and enhances the efficacy of certain antibiotics, particularly aminoglycosides.
According to Boyle's Law, increased pressure reduces the volume of gas bubbles in the blood — the primary mechanism for decompression sickness and arterial gas embolism.
At 2.8 ATA, gas bubble volume is reduced by approximately 64% compared to atmospheric pressure. This physical compression, combined with nitrogen washout through breathing 100% oxygen, eliminates intravascular and intratissue gas bubbles.
HBOT activates telomerase, induces senolytic effects, mobilizes stem cells, and enhances antioxidant defense through the hyperoxic-hypoxic paradox.
Repeated HBOT sessions activate telomerase (increasing telomere length by >20%), selectively eliminate senescent cells, mobilize bone marrow stem cells via NOS activation, and upregulate endogenous antioxidants (SOD, catalase, glutathione peroxidase) through hormetic stress responses.
A key insight in modern HBOT research is the hyperoxic-hypoxic paradox — the observation that repeated cycles of hyperoxia followed by return to normoxia generate a hormetic stress response. This paradox activates protective antioxidant pathways (SOD, catalase, glutathione peroxidase), stimulates angiogenesis, and drives the anti-aging effects including telomere lengthening and senescent cell clearance. The therapeutic benefit lies not in sustained hyperoxia, but in the dynamic oscillation between states.
+42%
Plasma O₂ Increase
at 3.0 ATA
−25%
Bubble Volume Reduction
at 2.8 ATA
Significant
VEGF Upregulation
angiogenesis
The Undersea and Hyperbaric Medical Society (UHMS) recognizes 14 conditions for which HBOT is approved as a standard-of-care treatment, with evidence levels ranging from A (strong RCT evidence) to B (observational/expert consensus).
Acute Ischemias
Intravascular gas bubbles causing arterial obstruction. HBOT reduces bubble volume and promotes nitrogen elimination.
Protocol
Pressure
2.8 – 3.0 ATA
Duration
90 min
Sessions
1 – 3 (emergency)
Frequency
Continuous until stable
Evidence basis: UHMS / Emergency Standard
Toxicities
HBOT accelerates CO elimination from hemoglobin and cytochrome oxidase, preventing delayed neurological sequelae.
Protocol
Pressure
2.4 – 2.8 ATA
Duration
90 min
Sessions
1 – 3 (emergency)
Frequency
Continuous until resolved
Evidence basis: UHMS / Emergency Standard
Infectious Diseases
HBOT is directly lethal to Clostridium perfringens and inhibits toxin production, used adjunctively with surgery and antibiotics.
Protocol
Pressure
2.0 – 2.5 ATA
Duration
90 min
Sessions
20 – 30
Frequency
Once daily, 5×/week
Evidence basis: UHMS / Standard of Care
Acute Ischemias
Reduces post-ischemic edema, preserves threatened tissue, and accelerates healing in traumatic crush injuries.
Protocol
Pressure
2.0 – 2.4 ATA
Duration
90 min
Sessions
30 – 40
Frequency
Once daily, 5×/week
Evidence basis: UHMS / FDA-Approved
Gas/Bubble Disorders
Primary treatment for nitrogen bubble formation in divers and compressed-air workers. Reduces bubble volume and promotes nitrogen elimination.
Protocol
Pressure
2.0 – 2.5 ATA
Duration
90 min
Sessions
20 – 30
Frequency
Once daily, 5×/week
Evidence basis: UHMS / Standard of Care
Wound Healing
Adjunctive treatment for chronic non-healing wounds, particularly diabetic foot ulcers with transcutaneous oxygen measurements <40 mmHg.
Protocol
Pressure
2.0 – 2.4 ATA
Duration
90 min
Sessions
20 – 30
Frequency
Once daily, 5×/week
Evidence basis: UHMS / Standard of Care
Infectious Diseases
When transfusion is not possible due to religious beliefs or unavailability, HBOT provides sufficient dissolved plasma oxygen to sustain life.
Protocol
Pressure
2.0 – 2.5 ATA
Duration
90 min
Sessions
20 – 40
Frequency
Once daily, 5×/week
Evidence basis: UHMS / Standard of Care
Infectious Diseases
Adjunctive therapy for brain abscesses, particularly those caused by anaerobic organisms. Enhances antibiotic efficacy and immune response.
Protocol
Pressure
2.0 – 2.5 ATA
Duration
90 min
Sessions
30 – 60
Frequency
Once daily, 5×/week
Evidence basis: UHMS / Standard of Care
Infectious Diseases
Adjunctive treatment for necrotizing fasciitis and Fournier's gangrene, reducing mortality and tissue loss when combined with surgery.
Protocol
Pressure
2.0 – 2.5 ATA
Duration
90 min
Sessions
20 – 30
Frequency
Once daily, 5×/week
Evidence basis: UHMS / Standard of Care
Infectious Diseases
Chronic osteomyelitis unresponsive to conventional therapy. HBOT enhances leukocyte killing, promotes angiogenesis in avascular bone.
Protocol
Pressure
2.0 – 2.4 ATA
Duration
90 min
Sessions
30 – 60
Frequency
Once daily, 5×/week
Evidence basis: UHMS / Standard of Care
Wound Healing
Treatment for osteoradionecrosis and soft tissue radiation necrosis. Promotes angiogenesis in hypoxic, hypovascular, hypocellular tissue.
Protocol
Pressure
2.0 – 2.4 ATA
Duration
90 min
Sessions
30 – 60
Frequency
Once daily, 5×/week
Evidence basis: UHMS / Standard of Care
Acute Ischemias
Salvage therapy for ischemic skin grafts and flaps. Reduces hypoxic necrosis and promotes graft survival through enhanced oxygenation.
Protocol
Pressure
2.0 – 2.4 ATA
Duration
90 min
Sessions
20 – 30
Frequency
Once daily, 5×/week
Evidence basis: UHMS / Standard of Care
Sensory Disorders
Adjunctive treatment when corticosteroids fail. Reverses cochlear hypoxia and reduces endolymphatic hydrops.
Protocol
Pressure
2.0 – 2.5 ATA
Duration
90 min
Sessions
10 – 20
Frequency
Once daily, 5×/week
Evidence basis: UHMS / Standard of Care
Sensory Disorders
Emergency treatment to preserve retinal layers and improve visual acuity through reversal of retinal ischemia.
Protocol
Pressure
2.0 – 2.8 ATA
Duration
90 min
Sessions
1 – 3 (emergency)
Frequency
Immediately, then daily
Evidence basis: UHMS / Emergency Standard
All 14 indications are recognized by the Undersea and Hyperbaric Medical Society (UHMS) and covered by Medicare/Medicaid in the United States. Evidence levels follow UHMS grading criteria.
Select a department to explore HBOT applications, evidence levels, and clinical protocols relevant to each specialty.
Orthopedics, Plastic, Cardiothoracic, Vascular
Standard-of-care adjunctive treatment for chronic osteomyelitis unresponsive to conventional therapy. HBOT enhances leukocyte killing in avascular bone and promotes neovascularization.
Protocol
Pressure
2.0 – 2.4 ATA
Duration
90 min
Sessions
30 – 60
Frequency
Once daily, 5×/week
Evidence basis: UHMS / FDA-Approved
Approved for acute traumatic ischemias. Reduces post-ischemic edema and preserves threatened tissue in severe crush injuries.
Protocol
Pressure
2.0 – 2.4 ATA
Duration
90 min
Sessions
10 – 20
Frequency
Once daily, 5×/week
Evidence basis: UHMS / FDA-Approved
Salvage therapy for ischemic reconstructive flaps and skin grafts. Reduces hypoxic necrosis through enhanced tissue oxygenation and angiogenesis.
Protocol
Pressure
2.0 – 2.4 ATA
Duration
90 min
Sessions
20 – 30
Frequency
Once daily, 5×/week
Evidence basis: UHMS / FDA-Approved
Emerging evidence shows HBOT accelerates recovery and reduces muscle damage following total knee arthroplasty and major orthopedic procedures.
Protocol
Pressure
2.0 ATA
Duration
90 min
Sessions
10 – 20
Frequency
Once daily, 5×/week
Evidence basis: Clinical Research
Adjunctive treatment for acute thermal burns. Reduces edema, promotes epithelialization, and decreases infection risk.
Protocol
Pressure
2.0 – 2.4 ATA
Duration
90 min
Sessions
20 – 30
Frequency
Once or twice daily
Evidence basis: UHMS / FDA-Approved
Investigational use for chronic stable ischemic heart disease and post-MI left ventricular function improvement through VEGF-mediated angiogenesis.
Protocol
Pressure
2.0 – 2.4 ATA
Duration
90 min
Sessions
30 – 40
Frequency
Once daily, 5×/week
Evidence basis: Investigational
TBI, Stroke, Dementia, Cognitive Enhancement
B-level evidence from clinical trials demonstrating improvements in neurocognitive deficits, post-concussion symptoms, and brain microstructure in mTBI patients.
Protocol
Pressure
1.5 – 2.0 ATA
Duration
60 – 90 min
Sessions
40 – 60
Frequency
Once daily, 5×/week
Evidence basis: Level B Evidence
Investigational adjunctive therapy for ischemic stroke recovery. HBOT promotes neuroplasticity, reduces peri-infarct hypoxia, and may improve functional outcomes.
Protocol
Pressure
2.0 ATA
Duration
90 min
Sessions
40 – 60
Frequency
Once daily, 5×/week
Evidence basis: Clinical Research
HBOT reverses chronic cerebral hypoperfusion and promotes angiogenesis in brain tissue. Clinical studies show improvements in cognitive function in vascular dementia patients.
Protocol
Pressure
2.0 ATA
Duration
90 min
Sessions
60
Frequency
Once daily, 5×/week
Evidence basis: Clinical Research
Randomized controlled trial demonstrated significant cognitive enhancements in healthy older adults, including memory and processing speed improvements correlated with increased cerebral blood flow.
Protocol
Pressure
2.0 ATA
Duration
90 min
Sessions
60
Frequency
Once daily, 5×/week
Evidence basis: RCT (Hadanny et al., 2020)
Emerging preclinical and early clinical evidence for Alzheimer's disease and Parkinson's disease. HBOT reduces neuroinflammation and promotes neurogenesis.
Protocol
Pressure
2.0 ATA
Duration
90 min
Sessions
40 – 60
Frequency
Once daily, 5×/week
Evidence basis: Preclinical / Early Phase
Radiation Injury, Tumor Sensitization
Standard-of-care treatment for osteoradionecrosis and soft tissue radiation necrosis. HBOT promotes angiogenesis in hypoxic, hypovascular, hypocellular irradiated tissue.
Protocol
Pressure
2.0 – 2.4 ATA
Duration
90 min
Sessions
30 – 60
Frequency
Once daily, 5×/week
Evidence basis: UHMS / FDA-Approved
Approved adjunctive treatment for radiation-induced hemorrhagic cystitis and proctitis, reducing bleeding and promoting mucosal healing.
Protocol
Pressure
2.0 – 2.4 ATA
Duration
90 min
Sessions
30 – 40
Frequency
Once daily, 5×/week
Evidence basis: UHMS / Standard of Care
Investigational use as neoadjuvant therapy to sensitize hypoxic solid tumors to radiotherapy and chemotherapy. Hypoxic tumor microenvironments are resistant to radiation; HBOT may reverse this resistance.
Protocol
Pressure
2.0 – 2.5 ATA
Duration
90 min
Sessions
Per radiation course
Frequency
Prior to each radiation fraction
Evidence basis: Investigational
Effective treatment for late radiation toxicity in breast cancer patients, including radiation dermatitis and tissue necrosis following breast-conserving surgery.
Protocol
Pressure
2.0 – 2.4 ATA
Duration
90 min
Sessions
30 – 40
Frequency
Once daily, 5×/week
Evidence basis: UHMS / Standard of Care
IBD, Ulcerative Colitis, Crohn's Disease
Systematic reviews indicate HBOT may achieve response rates exceeding 80% in acute severe ulcerative colitis refractory to conventional therapy, reversing chronic intestinal hypoxia.
Protocol
Pressure
2.0 – 2.4 ATA
Duration
90 min
Sessions
20 – 40
Frequency
Once daily, 5×/week
Evidence basis: Level A Meta-Analysis
Meta-analyses demonstrate significant mucosal healing and clinical remission in Crohn's disease patients treated with HBOT, particularly for perianal fistulizing disease.
Protocol
Pressure
2.0 – 2.4 ATA
Duration
90 min
Sessions
20 – 40
Frequency
Once daily, 5×/week
Evidence basis: Level A Meta-Analysis
HBOT reverses chronic intestinal hypoxia, reduces mucosal inflammation, and promotes epithelial healing. Considered a promising adjunctive therapy for IBD management.
Protocol
Pressure
2.0 – 2.4 ATA
Duration
90 min
Sessions
20 – 40
Frequency
Once daily, 5×/week
Evidence basis: Level A Meta-Analysis
Diabetic Foot, Metabolic Syndrome, Nephropathy
Most recognized HBOT application. Significantly improves complete healing rates in ischemic diabetic foot ulcers, reducing amputation rates when combined with standard wound care.
Protocol
Pressure
2.0 – 2.4 ATA
Duration
90 min
Sessions
30 – 40
Frequency
Once daily, 5×/week
Evidence basis: UHMS / FDA-Approved
Preclinical and early clinical studies demonstrate HBOT suppresses biomarkers of cell stress and kidney injury in diabetic models, suggesting renoprotective effects.
Protocol
Pressure
2.0 – 2.4 ATA
Duration
90 min
Sessions
20 – 30
Frequency
Once daily, 5×/week
Evidence basis: Clinical Research
Emerging evidence suggests HBOT may improve insulin sensitivity and reduce metabolic syndrome markers through enhanced mitochondrial function and reduced inflammation.
Protocol
Pressure
2.0 ATA
Duration
90 min
Sessions
20 – 30
Frequency
Once daily, 5×/week
Evidence basis: Investigational
Sudden Hearing Loss, Tinnitus
FDA-approved adjunctive treatment (2011) when corticosteroid therapy fails. Reverses cochlear hypoxia and reduces endolymphatic hydrops, improving hearing recovery rates.
Protocol
Pressure
2.0 – 2.5 ATA
Duration
90 min
Sessions
10 – 20
Frequency
Once daily, 5×/week
Evidence basis: UHMS / FDA-Approved
Investigational use for chronic tinnitus associated with cochlear hypoxia. Some clinical studies show improvement in tinnitus severity scores.
Protocol
Pressure
2.0 – 2.5 ATA
Duration
90 min
Sessions
10 – 20
Frequency
Once daily, 5×/week
Evidence basis: Clinical Research
Retinal Artery Occlusion, Retinal Ischemia
Emergency FDA-approved treatment. Early HBOT intervention (within 24 hours) preserves retinal layers and improves visual acuity by reversing acute retinal ischemia.
Protocol
Pressure
2.0 – 2.8 ATA
Duration
90 min
Sessions
1 – 3 (emergency)
Frequency
Immediately, then daily
Evidence basis: UHMS / FDA-Approved
Investigational use for early-stage diabetic retinopathy. HBOT may reduce retinal hypoxia and slow progression of vascular changes.
Protocol
Pressure
2.0 – 2.4 ATA
Duration
90 min
Sessions
20 – 30
Frequency
Once daily, 5×/week
Evidence basis: Investigational
PTSD, Depression, Anxiety
Clinical trials demonstrate HBOT improves brain microstructure functionality and alleviates PTSD symptoms in veterans with treatment-resistant PTSD. Significant improvements in PTSD checklist scores.
Protocol
Pressure
1.5 – 2.0 ATA
Duration
60 – 90 min
Sessions
40 – 60
Frequency
Once daily, 5×/week
Evidence basis: Level B Evidence (RCT)
Emerging research investigates HBOT for treatment-resistant depression through neuroplasticity enhancement, BDNF upregulation, and reduction of neuroinflammation.
Protocol
Pressure
1.5 – 2.0 ATA
Duration
60 – 90 min
Sessions
20 – 40
Frequency
Once daily, 5×/week
Evidence basis: Investigational
Physical Performance, Cognitive Aging
Randomized controlled trial demonstrated HBOT improves maximal physical performance and cardiac perfusion in sedentary older adults, enhancing exercise capacity and cardiovascular function.
Protocol
Pressure
2.0 ATA
Duration
90 min
Sessions
40 – 60
Frequency
Once daily, 5×/week
Evidence basis: RCT (Doenyas-Barak et al., 2024)
HBOT reverses age-related cerebral hypoperfusion and promotes angiogenesis in brain tissue, potentially preventing or slowing cognitive decline in aging populations.
Protocol
Pressure
2.0 ATA
Duration
90 min
Sessions
60
Frequency
Once daily, 5×/week
Evidence basis: RCT (Hadanny et al., 2020)
First human evidence of telomere lengthening (>20%) and senescent cell clearance through 60 HBOT sessions in healthy older adults, representing a novel anti-aging intervention.
Protocol
Pressure
2.0 ATA
Duration
90 min
Sessions
60
Frequency
Once daily, 5×/week
Evidence basis: Hadanny et al., 2020 (RCT)
The following departments do not currently have direct HBOT applications based on available evidence. This does not preclude future research or indirect roles in patient care pathways.
Exclusion Criteria
Departments are listed here when: (1) no peer-reviewed evidence supports direct HBOT application in their primary scope of practice; (2) the department's function is diagnostic or supportive rather than therapeutic; or (3) HBOT would be managed by a referring department rather than the listed specialty itself.
Diagnostic laboratories (Microbiology, Hematology, Biochemistry) are analytical entities that process specimens and generate results. While HBOT relies on these departments for patient assessment — including transcutaneous oximetry and microbiological wound cultures — the therapy itself is not applied within these disciplines. No current evidence supports HBOT as a diagnostic modality.
Role in HBOT Program:
Supportive — provides pre/post HBOT biomarker assessment
The Genetics Clinic manages hereditary conditions, chromosomal disorders, and genetic counseling. There is currently no scientific evidence supporting the use of HBOT in the management of genetic disorders. While HBOT modulates gene expression through HIF pathways, this does not translate to therapeutic benefit for primary genetic conditions.
Role in HBOT Program:
No current or projected clinical application
While preclinical research is emerging on HBOT for liver regeneration and hepatic ischemia-reperfusion injury, this has not yet translated to established clinical practice. Liver transplant centers have explored HBOT as a preservation strategy, but this remains strictly investigational with no approved protocols.
Role in HBOT Program:
Preclinical research only; no established clinical protocols
While critically ill patients may occasionally require HBOT for conditions such as gas gangrene or carbon monoxide poisoning, the logistical challenges of managing ventilated, hemodynamically unstable patients in a hyperbaric chamber are significant. Standard ICU monitoring equipment is not compatible with hyperbaric environments. Monoplace chambers limit access for emergency interventions.
Role in HBOT Program:
Occasional referral for specific indications (CO poisoning, gas gangrene)
Medical Imaging (CT, MRI, PET, Nuclear Medicine Theranostics) serves a purely diagnostic and interventional imaging function. HBOT does not alter imaging protocols or radiopharmaceutical uptake in any clinically meaningful way. These departments support HBOT patient selection and monitoring but are not sites of HBOT application.
Role in HBOT Program:
Supportive — pre-treatment imaging and perfusion assessment
While emerging research explores HBOT for chronic kidney disease and diabetic nephropathy, it is not currently a treatment modality utilized within a standard dialysis unit. Dialysis patients have complex vascular access requirements and hemodynamic instability that complicate hyperbaric treatment. This remains a preclinical area of investigation.
Role in HBOT Program:
No current clinical application; preclinical research ongoing
This list reflects the evidence base as of 2025. Ongoing research may establish new indications. Departments listed here may still play important roles in patient selection, monitoring, and follow-up within a comprehensive HBOT program.
Beyond established clinical indications, HBOT demonstrates compelling evidence for healthy aging, cognitive enhancement, and performance optimization — positioning it as a cornerstone of modern longevity medicine.
>20%
Increase in telomere length
Landmark 2020 study demonstrated >20% increase in PBMC telomere length after 60 HBOT sessions in healthy older adults — the first human evidence of therapeutic telomere lengthening.
Detailed Mechanism
HBOT activates telomerase, the enzyme responsible for telomere maintenance and extension. Repeated daily sessions create a hormetic stimulus that upregulates telomerase reverse transcriptase (TERT) expression.
Protocol
Pressure
2.0 ATA
Duration
90 min
Sessions
60
Frequency
Once daily, 5×/week
Evidence basis: Hadanny et al., 2020 (RCT)
37%
Reduction in senescent T-cells
The same landmark study demonstrated significant reduction in senescent (dysfunctional) immune cells — the first senolytic effect demonstrated through a non-pharmacological intervention.
Detailed Mechanism
HBOT induces selective apoptosis of senescent cells through ROS-mediated signaling pathways. Senescent cells accumulate with age and drive the 'inflammaging' phenotype associated with age-related diseases.
Protocol
Pressure
2.0 ATA
Duration
90 min
Sessions
60
Frequency
Once daily, 5×/week
Evidence basis: Hadanny et al., 2020 (RCT)
16.5%
Improvement in attention & processing speed
Randomized controlled trial in healthy older adults showed significant cognitive enhancements including memory, processing speed, and executive function improvements correlated with increased cerebral blood flow.
Detailed Mechanism
HBOT increases regional cerebral blood flow, promotes neuroplasticity through BDNF upregulation, reduces neuroinflammation, and supports hippocampal neurogenesis — all mechanisms diminished with normal aging.
Protocol
Pressure
2.0 ATA
Duration
90 min
Sessions
60
Frequency
Once daily, 5×/week
Evidence basis: Hadanny et al., 2020 (RCT)
8×
Increase in circulating stem cells
HBOT mobilizes bone marrow stem cells into circulation at rates up to 8-fold above baseline, enhancing the body's regenerative capacity for tissue repair and organ maintenance.
Detailed Mechanism
Hyperoxia activates endothelial nitric oxide synthase (eNOS), which triggers stem cell mobilization from bone marrow niches. Increased circulating stem progenitor cells (SPCs) differentiate into various cell types to repair damaged tissues.
Protocol
Pressure
2.0 – 2.4 ATA
Duration
90 min
Sessions
20 – 40
Frequency
Once daily, 5×/week
Evidence basis: Thom et al., 2006 / Clinical Research
50%
Faster muscle recovery
Systematic review and meta-analysis demonstrates consistent benefits including 30-50% faster muscle recovery, reduced exercise-induced muscle damage, decreased inflammation markers, and enhanced endurance capacity.
Detailed Mechanism
HBOT increases oxygen availability to muscle tissue, accelerating ATP production and enhancing natural repair mechanisms. It reduces pro-inflammatory cytokines (IL-6, TNF-α) that impede recovery and promotes satellite cell activation for muscle regeneration.
Protocol
Pressure
1.5 – 2.4 ATA
Duration
60 – 90 min
Sessions
10 – 20 per cycle
Frequency
Post-exercise or daily
Evidence basis: Systematic Review & Meta-Analysis
3×
Increase in collagen III formation
HBOT stimulates collagen III formation and increases overall collagen production through growth factor upregulation, supporting skin elasticity, joint health, and connective tissue integrity.
Detailed Mechanism
Hyperoxia upregulates VEGF, PDGF, and FGF, promoting fibroblast proliferation and collagen synthesis. HBOT also enhances hydroxylation of proline and lysine residues, critical steps in collagen cross-linking and tissue strength.
Protocol
Pressure
2.0 – 2.4 ATA
Duration
90 min
Sessions
20 – 40
Frequency
Once daily, 5×/week
Evidence basis: Clinical Research
HBOT creates a unique biological environment: repeated cycles of high-pressure oxygen followed by return to normal pressure generate a hormetic stress response. This paradox — using oxygen to fight oxidative aging — activates the body's most powerful endogenous repair mechanisms, including telomerase activation, senolytic pathways, and stem cell mobilization.
Key peer-reviewed studies supporting HBOT applications across clinical specialties and longevity medicine, with evidence levels and direct links to source publications.
Evidence Levels:
Hadanny A, Daniel-Kotovsky M, Suzin G, et al. · Aging (Albany NY) · 2020
Key Finding
60 HBOT sessions increased PBMC telomere length by >20% and significantly reduced senescent T-cells — first human evidence of non-pharmacological telomere lengthening.
Amir H, Malka DK, Gil S, et al. · Aging (Albany NY) · 2020
Key Finding
HBOT induced significant cognitive enhancements in healthy aging adults via mechanisms involving regional changes in cerebral blood flow.
Fu Q, Duan R, Sun Y, Li Q. · Redox Biology · 2022
Key Finding
First comprehensive overview of HBOT in aging and geriatric research. Therapeutic targets of HBOT overlap considerably with hallmarks of aging.
Hadanny A, Sasson E, Copel L, et al. · BMC Geriatrics · 2024
Key Finding
HBOT improved maximal physical performance and cardiac perfusion in sedentary older adults, including enhanced VO2 max and cardiovascular function.
Singh AK, Jha DK, Jena A, et al. · European Journal of Gastroenterology & Hepatology · 2021
Key Finding
HBOT achieved response rates exceeding 80% in both ulcerative colitis and Crohn's disease, with significant mucosal healing demonstrated.
Wolf G, Cifu D, Baugh L, et al. · Neurology · 2012
Key Finding
B-level evidence supporting HBOT for mild TBI and post-concussion syndrome, showing improvements in neurocognitive deficits and post-concussion symptoms.
Doenyas-Barak K, Catalogna M, Kutz I, et al. · PLoS One · 2022
Key Finding
HBOT significantly improved PTSD checklist scores and demonstrated measurable improvements in brain microstructure on advanced MRI in treatment-resistant PTSD veterans.
Huang X, Wang R, Zhang Z, et al. · Frontiers in Physiology · 2021
Key Finding
First meta-analysis on HBOT for exercise performance and recovery. Consistent benefits in muscle recovery, reduced inflammation, and enhanced endurance capacity.
The HBOT evidence base spans over 258 peer-reviewed publications, including multiple Level I randomized controlled trials and systematic reviews. The strongest evidence supports wound healing, decompression sickness, and carbon monoxide poisoning, while emerging Level I evidence now supports longevity and cognitive enhancement applications.
8+
Level I RCTs
Highest evidence
5+
Meta-Analyses
Pooled evidence
258+
Total Citations
Comprehensive base
A phased framework for integrating HBOT services into a hospital programme, addressing clinical, operational, and market positioning dimensions.
Create a specialized department staffed with certified hyperbaric physicians, trained nurses, and hyperbaric technicians. A multiplace chamber (6–12 seats) enables simultaneous treatment of multiple patients and allows full monitoring of critically ill patients.
Key Actions:
Develop standardized referral pathways from Surgery, Internal Medicine, Oncology, and Geriatric departments for FDA-approved indications. Establish transcutaneous oximetry screening for wound care patients.
Key Actions:
Develop premium wellness packages targeting healthy individuals seeking cognitive enhancement, anti-aging benefits, and athletic performance optimization. Position as a differentiated offering in the growing longevity medicine market.
Key Actions:
Establish clinical research partnerships to conduct trials on emerging indications, contributing to the international hyperbaric medicine evidence base.
Key Actions:
The global longevity medicine market is projected to reach $44.2 billion by 2030. HBOT, with its unique combination of FDA-approved clinical applications and emerging evidence for healthy aging, sits at the intersection of clinical integration and premium wellness. A dedicated Hyperbaric Medicine Unit creates a clear competitive position for hospitals and longevity operators entering the longevity-medicine market.
$44.2B
Longevity Market by 2030
258+
Peer-reviewed citations
Dual
Clinical + Wellness Revenue
All 24 peer-reviewed sources cited in this clinical resource, with direct links to original publications.
24
Total Sources
2
RCTs & Meta-Analyses
13
Systematic Reviews
1
Clinical Guidelines
Kahle AC, Cooper JS. · StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing · 2023
Ortega MA, Fraile-Martinez O, García-Montero C, et al. · Medicina · 2021
Hadanny A, Daniel-Kotovsky M, Suzin G, et al. · Aging (Albany NY) · 2020
Amir H, Malka DK, Gil S, Rahav BG, Merav C, et al. · Aging (Albany NY) · 2020
Fu Q, Duan R, Sun Y, Li Q. · Redox Biology · 2022
MacLaughlin KJ, et al. · PMC — National Library of Medicine · 2023
Fu Q, Duan R, Sun Y, Li Q. · Redox Biology · 2022
Gottfried I, Schottlender N, Ashery U. · Biomolecules · 2021
Undersea and Hyperbaric Medical Society (UHMS). · UHMS Official Publication · 2020
Multiple Authors. · Scientific Reports · 2025
Růžička J, et al. · PMC — National Library of Medicine · 2021
Tian M. · Medical Gas Research · 2025
Stoekenbroek RM, Santema TB, Legemate DA, et al. · European Journal of Vascular and Endovascular Surgery · 2014
Singh AK, Jha DK, Jena A, et al. · European Journal of Gastroenterology & Hepatology · 2021
Wolf G, Cifu D, Baugh L, et al. · Neurology · 2012
Xu Y, Wang Q, Qu Z, et al. · Cell Transplantation · 2019
Multiple Authors. · PMC — National Library of Medicine · 2025
Multiple Authors. · ScienceDirect — Nitric Oxide · 2023
Celebi ARC. · Clinical Ophthalmology · 2021
Doenyas-Barak K, Catalogna M, Kutz I, et al. · PLoS One · 2022
Hadanny A, Sasson E, Copel L, Daniel-Kotovsky M, et al. · BMC Geriatrics · 2024
Huang X, Wang R, Zhang Z, Wang G, Gao B. · Frontiers in Physiology · 2021
Gupta M, et al. · Frontiers in Aging · 2024
Multiple Authors. · SciVision Publishers — Regenerative Medicine · 2025
All references accessed April 2025. DOI links direct to original publications. This resource is intended for clinical and educational purposes only and does not constitute medical advice.